Articles tagged "Highly-sensitized"

2022 American Transplant Congress
CIAT: A New Kidney Exchange Program with Better Options for Highly Sensitized and Long Waiting Patients
M. d. Klerk¹, J. Kal¹, D. L. Roelen², M. Betjes¹, A. Weerd de¹, M. Reinders¹, M. Kho¹, K. Glorie³, J. I. Roodnat¹
¹Internal Medicine, Erasmus MC Transplant Institute, Rotterdam, Netherlands, ²Immunology, Leids UMC, Netherlands, ³Econometrics, EUR, Rotterdam, Netherlands
*Purpose: A number of alternative, both living and deceased donor kidney transplant programs have been developed for incompatible pairs and difficult to match patients. The…
2022 American Transplant Congress
Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population
A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran
University of Illinois at Chicago, Chicago, IL
*Purpose: This study assessed outcomes of hepatitis C virus (HCV) donor positive to recipient negative (D+/R-) kidney transplants (KT) in high immunologic risk patients. Literature…
2022 American Transplant Congress
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
R. Zhang¹, S. Ge¹, M. Chu¹, J. Kahwaji², A. Karasyov¹, D. Lovato¹, A. Vo², J. Choi², M. Toyoda¹, S. Jordan²
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Post-transplant immunosuppression with “everolimus + reduced dose tacrolimus” (Ev + Taclow) is reported to reduce the risk of viral infections compared to standard doses…
2022 American Transplant Congress
Stem Cell Donor-Derived CPRA Better Reflects Sensitization Than Current CPRA
K. Lindblad¹, C. Murphey², P. Lalli³, J. Lunz⁴, L. Gragert⁵
¹UNOS, Richmnd, VA, ²Southwest Immunodiagnostics, Inc., San Antonio, TX, ³Carolinas Medical Center, Charlotte, NC, ⁴LifeLink Foundation Transplant Immunology Lab, Tampa, FL, ⁵Tulane University School of Medicine, New Orleans, LA
*Purpose: The OPTN Histocompatibility Committee proposes replacing the current calculated panel reactive antibody (CPRA), based on HLA haplotype frequencies from ~14,000 deceased kidney donors, with…
2021 American Transplant Congress
Kidney Transplantation in Very Highly-Sensitized Patients with Maastricht Type III Non-heart-Beating Donors
F. Villanego¹, A. Mazuecos¹, L. Vigara¹, V. Lopez², G. Bernal³, A. Rodriguez-Benot⁴, M. de Gracia⁵, P. Castro⁶, A. Alvarez⁶
¹Department of Nephrology, Hospital Puerta del Mar, Cadiz, Spain, ²Department of Nephrology, Hospital Carlos Haya, Malaga, Spain, ³Department of Nephrology, Hospital Virgen del Rocio, Sevilla, Spain, ⁴Department of Nephrology, Hospital Reina Sofia, Cordoba, Spain, ⁵Department of Nephrology, Hospital Virgen de las Nieves, Granada, Spain, ⁶Andalusian Transplant Coordination, Sevilla, Spain
*Purpose: In 2012, a kidney transplant (KT) program for very highly-sensitized (VHS) patients (PRA ≥ 95%) based on virtual crossmatch began in Andalusia (Spanish region).…
2021 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
B. Oh¹, F. Messner², Y. Guo¹, G. Brandacher¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Visceral, Transplant and Thoracic Surgery, University of Innsbruck, Innsbruck, Austria
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
2021 American Transplant Congress
Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Sethi¹, S. Williamson¹, C. Myers¹, K. Lim¹, M. Gillespie¹, S. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…
2021 American Transplant Congress
Sensitized Lung Candidates Experience Reduced Access to Donor Organs
K. Lindblad¹, R. Goff², D. Stewart²
¹UNOS, Richmond, VA, ²UNOS, Richmnd, VA
*Purpose: Most studies of sensitization in transplant candidates have focused on kidney candidates, and unacceptable antigens (UAs) for non-kidney candidates are believed to be underreported.…
2021 American Transplant Congress
HLA Haplotype Frequency and Racial Disparities in Access to Transplant Among Highly Sensitized Kidney Transplant Candidates
L. Gragert¹, M. Kadatz², D. Chang², H. Gebel³, D. Stewart⁴, E. Kransdorf⁵, S. Brar², S. Vaishnav², J. Gill², J. Lan²
¹Tulane University, New Orleans, LA, ²University of British Columbia, Vancouver, BC, Canada, ³Emory University, Atlanta, GA, ⁴UNOS, Richmond, VA, ⁵Cedars-Sinai, Beverly Hills, CA, Canada
*Purpose: Despite implementation of the Kidney Allocation System (KAS) which prioritizes sensitized patients, sensitized Black individuals are less likely to receive a transplant than non-Black…
2021 American Transplant Congress
Safety and Tolerability of Tacrolimus Extended-Release (astagraf Xl) in Hla Sensitized Kidney Transplant Recipients: A Single Center Experience
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, K. Lim, M. Gillespie, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Pill burden is a limitation in kidney transplant. Tacrolimus extended-release (Astagraf XL) is a once daily formulation approved for kidney transplantation. Increased compliance could…